Patents Assigned to Array Biopharma Inc.
  • Publication number: 20240190843
    Abstract: This Invention relates to a hemihydrate crystalline form of (S)-1?-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4?-piperidin]-1-amine free base (Form 1). The invention also relates to pharmaceutical compositions comprising this crystalline form, and to methods of using the crystalline form and such compositions for the treatment of abnormal cell growth, such as cancer, in a mammal.
    Type: Application
    Filed: March 30, 2022
    Publication date: June 13, 2024
    Applicant: Array BioPharma Inc.
    Inventors: Katie Keaton BROWN, Aaron Keith GOODWIN
  • Patent number: 11998545
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: June 27, 2023
    Date of Patent: June 4, 2024
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren
  • Publication number: 20240174666
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
    Type: Application
    Filed: August 29, 2023
    Publication date: May 30, 2024
    Applicant: Array BioPharma Inc.
    Inventors: Ronald Jay Hinklin, Shelley Allen, Patrick Michael Doerner Barbour, Adam Wade Cook, Joshua Ryan Dahlke, John Joseph Gaudino, Ellen Ruth Laird, Oren Teague McNulty, Qian Zhao
  • Patent number: 11964989
    Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 20, 2022
    Date of Patent: April 23, 2024
    Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • Patent number: 11964988
    Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: April 23, 2024
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Dean Kahn, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L McKenney, Andrew T. Metcalf, David A. Moreno, Brett Prigaro, Ginelle A. Ramann, Li Ren, Shane M. Walls, Hailong Zhang
  • Publication number: 20240124453
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: November 17, 2023
    Publication date: April 18, 2024
    Applicant: Array BioPharma Inc.
    Inventors: James Francis BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam Wade COOK, Mohamed S. A. ELSAYED, Jay Bradford FELL, John P. FISCHER, Ronald Jay HINKLIN, Yutong JIANG, Oren Teague MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina Elizabeth WONG
  • Publication number: 20240124474
    Abstract: This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
    Type: Application
    Filed: November 1, 2023
    Publication date: April 18, 2024
    Applicant: Array BioPharma Inc.
    Inventors: Mark Laurence BOYS, Bryan Daniel ELLIS, John Joseph GAUDINO, Erik James HICKEN, Ellen Ruth LAIRD, Nicholas Charles LAZZARA, Bradley Jon NEWHOUSE, Spencer Phillip PAJK
  • Patent number: 11932633
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: March 19, 2024
    Assignees: Mirati Therapeutics, Inc., Array Biopharma Inc.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, James F. Blake, Mark Joseph Chicarelli, Jay Bradford Fell, John P. Fischer, Erik James Hicken, Pavel Savechenkov, Tony Tang, Guy P. A. Vigers, Henry J. Zecca
  • Patent number: 11884664
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: January 30, 2024
    Assignee: Array BioPharma Inc.
    Inventors: James Francis Blake, Mark Laurence Boys, Mark Joseph Chicarelli, Adam Wade Cook, Mohamed S. A. Elsayed, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Yutong Jiang, Oren Teague McNulty, Macedonio J. Mejia, Martha E. Rodriguez, Christina Elizabeth Wong
  • Patent number: 11851434
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: December 26, 2023
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, David A. Moreno, Li Ren, Shane M. Walls
  • Patent number: 11834453
    Abstract: This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: December 5, 2023
    Assignee: Array BioPharma Inc.
    Inventors: Mark Laurence Boys, Bryan Daniel Ellis, John Joseph Gaudino, Erik James Hicken, Ellen Ruth Laird, Nicholas Charles Lazzara, Bradley Jon Newhouse, Spencer Phillip Pajk
  • Patent number: 11813246
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: November 14, 2023
    Assignees: AstraZeneca AB, Array BioPharma, Inc.
    Inventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
  • Patent number: 11807651
    Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: November 7, 2023
    Assignees: Loxo Oncology Inc., Array BioPharma Inc.
    Inventors: Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
  • Patent number: 11780835
    Abstract: Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: October 10, 2023
    Assignee: Array BioPharma Inc.
    Inventors: Ronald Jay Hinklin, Shelley Allen, Patrick Barbour, Adam Cook, Joshua Dahlke, John Gaudino, Ellen Laird, Oren T. McNulty, Qian Zhao
  • Publication number: 20230241066
    Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.
    Type: Application
    Filed: January 3, 2023
    Publication date: August 3, 2023
    Applicant: Array BioPharma Inc.
    Inventors: Donald T. Corson, Christopher M. Lindemann, Daniel J. Watson
  • Publication number: 20230190749
    Abstract: Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 22, 2023
    Applicant: Array BioPharma Inc.
    Inventors: Patrice A. Lee, Shannon L. Winski, Kevin Koch
  • Patent number: 11648243
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 16, 2023
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, James Collier, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. Mcfaddin, Megan L. Mckenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Ginelle A. Ramann, Tony P. Tang, Li Ren, Shane M. Walls
  • Publication number: 20230142839
    Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
    Type: Application
    Filed: September 8, 2022
    Publication date: May 11, 2023
    Applicant: Array BioPharma Inc.
    Inventors: Joseph P. LYSSIKATOS, Julie Marie HICKS, Fredrik P. MARMSATER, Qian ZHAO
  • Patent number: 11634409
    Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: April 25, 2023
    Assignee: Array BioPharma Inc.
    Inventors: Patrick Michael Barbour, Katie Keaton Brown, Adam Wade Cook, Erik James Hicken, Dean Russell Kahn, Ellen Ruth Laird, Andrew Terrance Metcalf, David Austin Moreno, Bradley Jon Newhouse, Spencer Phillip Pajk, Brett Joseph Prigaro, Li Ren, Eugene Tarlton
  • Patent number: RE49556
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: June 20, 2023
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie